Heart Failure: Molecules, Mechanisms and Therapeutic Targets / Edition 1by Novartis Foundation
Pub. Date: 09/25/2006
Over the past five years, there has been dramatic progress in unravelling the cellular circuitry involved in cardiac failure, as well as in normal cardiac growth, development and apoptosis. These studies have revealed new and unanticipated therapeutic targets in the heart. In addition, recent advances in understanding the role of stem cells in cardiac repair have… See more details below
Over the past five years, there has been dramatic progress in unravelling the cellular circuitry involved in cardiac failure, as well as in normal cardiac growth, development and apoptosis. These studies have revealed new and unanticipated therapeutic targets in the heart. In addition, recent advances in understanding the role of stem cells in cardiac repair have suggested strategies for cardiac repair and regeneration once thought impossible. This book brings together investigators working on basic mechanisms of cardiac growth, function and dysfunction, along with those searching for novel therapeutic strategies for cardiac disease. The discussions in this book always return to the same basic problem: how to use new data from the biological studies to design novel therapies for the treatment of cardiac dysfunction following myocardial infarction, cardiac hypertrophy, hypertension and other stresses.
Table of Contents
Introduction (Eric N. Olson).
Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation (Eric N. Olson, Johannes Backs and Timothy A. McKinsey) .
A novel mechanism of mechanical stress-induced hypertrophy (Hiroshi Akazawa, Yunzeng Zou and Issei Komuro) .
Controlling cardiomyocyte survival (N. de Jonge, M. J. Goumans, Daan Lips, Rutger Hassink, Eva J. Vlug, Roy van der Meel, Christopher Donald Emmerson, Joppe Nijman, Leon de Windt and Pieter A. Doevendans) .
Mechanisms of angiotensin II-dependent progression to heart failure (Mona Nemer, Nassim Dali-Youcef, Hao Wang, Anne Aries and Pierre Paradis) .
Alterations in myocardial gene expression as a basis for cardiomyopathies and heart failure (Matthew R. Taylor and Michael R. Bristow) .
Role of the insulin-like growth factor 1 (IGF1)/phosphoinositide-3-kinase (PI3K) pathway mediating physiological cardiac hypertrophy (Julie R. McMullen and Seigo Izumo).
Role of Akt in cardiac growth and metabolism(Anthony J. Muslin and Brian DeBosch).
Novel therapy for heart failure and exercise-induced ventricular tachycardia based on ‘fixing’ the leak in ryanodine receptors (Andrew R. Marks).
General discussion I.
Phospholamban as a therapeutic modality in heart failure (Guoxiang Chu and Evangelia G. Kranias).
Sarcomere protein gene mutations and inherited heart disease: a b-cardiac myosin heavy chain mutation causing endocardial fibroelastosis and heart failure (Mitsuhiro Kamisago, Joachim P. Schmitt, Dennis McNamara, Christine Seidman and Jonathan G. Seidman).
The cardiomyocyte cell cycle (Pascal J. E. Lafontant and Loren J. Field).
Restoration of cardiac function with progenitor cells (Carmen Urbich, Lothar Rössig and Stefanie Dimmeler).
Signalling pathways in cardiac regeneration (Maria Paola Santini, Nadine Winn and Nadia Rosenthal).
Beyond small molecule drugs for heart failure: prospects for gene therapy (Kenneth R. Chien).
Dual roles of telomerase in cardiac protection and repair (Michael D. Schneider).
Final general discussion.
Closing remarks: historical perspective (Arnold M. Katz).
Index of contributors.
and post it to your social network
Most Helpful Customer Reviews
See all customer reviews >